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Summary of main points 
Pooling someone’s rectal, pharyngeal and FCU/VVS samples into one container was as 
accurate as individual samples for diagnosing gonorrhoea but 3% less sensitive for 
chlamydia. Pooled specimens were more accurate, and cost-effective, at diagnosing 
gonorrhoea and chlamydia than FCU/VVS alone. 
 
Word count 3235 (however equivalent to 3000 as 235 words used for the references to 
SYSTEMATIC Part 1 paper).  






Sexual history does not accurately identify those with extragenital Neisseria gonorrhoeae 
(NG) and Chlamydia trachomatis (CT) so universal extragenital sampling is recommended. 
Nucleic acid amplification tests (NAATs) are expensive. If urogenital, plus rectal and 
pharyngeal, samples are analysed the diagnostic cost is trebled. Pooling samples into one 
NAAT container would cost the same as urogenital samples alone. We compared clinician 
triple samples analysed individually with self-taken pooled samples for diagnostic accuracy, 
and cost, in MSM and females. 
 
Methods: 
Prospective, convenience, sample in UK sexual health clinic. Randomised order of clinician 
and self-samples from pharynx, rectum, plus first catch urine (FCU) in MSM and 
vulvovaginal swabs (VVS) in females, for NG and CT detection. 
 
Results: 
Of 1793 participants (1284 females, 509 MSM), 116 had NG detected (75 urogenital, 83 
rectum, 72 pharynx). 276 had CT detected (217 urogenital, 249 rectum, 63 pharynx).   
There was no difference in sensitivities between clinician triple samples and self-pooled 
specimens for NG (99.1%, 98.3%) but clinician samples analysed individually identified 3% 
more chlamydia infections than pooled (99.3%, 96.0%; p=0.027). However, pooled 
specimens identified more infections than VVS/FCU alone. Pooled specimens missed 2 NG 
and 11 CT infections, whereas VVS/FCU missed 41 NG and 58 CT infections. Self-taken 
pooled specimens were the most cost-effective.  
 
Conclusions: 
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Just FCU/VVS testing missed many infections. Self-taken pooled samples were as sensitive 
as clinician triple samples for identifying NG, but clinician samples analysed individually 
identified 3% more CT infections than pooled. The extragenital sampling was achievable at 










Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) are the most common 
bacterial sexually transmitted infections (STIs) worldwide.[1] Both infections can be 
asymptomatic in males and females, but lead to serious sequelae if untreated.[2,3] In 
addition to infecting the urogenital tract, both can infect the rectum and pharynx (extragenital 
sites), usually with no symptoms. Infections may be present in urogenital and/or extragenital 
sites.  
 
Most guidelines[2-5] suggest extragenital screening in men who have sex with men (MSM) 
and females based on reported sexual history of receptive anal sex and giving oral sex. 
However, several studies indicate that sexual history does not accurately identify those with 
extragenital infections so universal extragenital sampling is being recommended.[6-11] 
 
Nucleic acid amplification tests (NAATs) are expensive. If rectal and pharyngeal samples are 
taken with urogenital samples (first-catch urine [FCU] in MSM and vulvovaginal swab [VVS] 
in females), the diagnostic cost is trebled. This increased cost in all females and MSM is 
unaffordable for most publicly funded sexual health services.[12-17]  
 
Self-taken extragenital samples are as accurate at detecting NG and CT as clinician-taken 
samples, and are more cost-effective. [Wilson JD, Wallace HE, Loftus-Keeling M, et al. 
Swab-yourself trial with economic monitoring and testing for infections collectively 
(SYSTEMATIC): Part 1. A diagnostic accuracy, and cost-effectiveness, study comparing 
clinician-taken versus self-taken rectal and pharyngeal samples for the diagnosis of 
gonorrhoea and chlamydia. Accepted by Clin Infect Dis.] These can be performed by 
individuals along with FCU/VVS samples. If rectal, pharyngeal, FCU/VVS, samples were 
pooled into one NAAT container and analysed together, laboratory testing costs for triple-site 
samples would cost the same as urogenital samples alone. However, NAAT sensitivity and 
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specificity may be affected by the pooling process. Six studies in MSM have compared 
pooled triple-site samples with triple-site samples analysed individually to detect NG and 
CT.[12-17] All identified reduced sensitivity of NG and CT in pooled specimens and no 
optimum pooling technique was reported. No studies have compared pooled specimens in 
females, yet their prevalence of rectal chlamydia is as high as MSM.[11] 
 
A pooling technique of self-taken, triple-site, pooled-samples that was as accurate as 
clinician-samples analysed individually, would enable testing of all potentially infected sites 
without increasing diagnostic costs. This complete testing would prevent the false 
reassurance of negative FCU/VVS where extragenital infections were missed.  
 
We therefore performed a study comparing clinician-taken rectal and pharyngeal swabs, 
plus FCU/VVS, analysed individually versus self-taken rectal, pharyngeal, and FCU/VVS 





The full methods are described elsewhere. [Wilson JD, Wallace HE, Loftus-Keeling M, et al. 
Swab-yourself trial with economic monitoring and testing for infections collectively 
(SYSTEMATIC): Part 1. A diagnostic accuracy, and cost-effectiveness, study comparing 
clinician-taken versus self-taken rectal and pharyngeal samples for the diagnosis of 
gonorrhoea and chlamydia. Accepted by Clin Infect Dis.] Briefly, females and MSM, 16 years 
and over presenting to Leeds Sexual Health between January 2015 and September 2016 to 
be tested for NG and CT, and willing to perform self-taken swabs in addition to standard 
clinician performed swabs, were invited to participate. Exclusion criteria were antibiotics in 
the preceding 28 days, and/or rectal symptoms. Written consent was obtained with inclusion 
allowed only once. Details of age, sex, and urogenital symptoms suggestive of a bacterial 
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STI (vaginal discharge, intermenstrual/post-coital bleeding, deep dyspareunia, lower 
abdominal pain in females; urethral discharge, dysuria, testicular pain in MSM), were 
collected.  
 
Participants had three sets of samples: 1. Clinician-taken rectal and pharyngeal swabs 
analysed individually (Clinician); 2. Self-taken rectal, pharyngeal and VVS/FCU analysed 
individually (Self); 3. Self-taken rectal, pharyngeal and VVS/FCU analysed as pooled 
specimen (Pooled). This paper reports the results of clinician-rectal and pharyngeal swabs, 
with VVS/FCU, analysed individually versus pooled self-taken rectal and pharyngeal swabs, 
plus VVS/FCU. Results of clinician compared with self-taken extragenital samples analysed 
individually are reported elsewhere. [Wilson JD, Wallace HE, Loftus-Keeling M, et al. Swab-
yourself trial with economic monitoring and testing for infections collectively (SYSTEMATIC): 
Part 1. A diagnostic accuracy, and cost-effectiveness, study comparing clinician-taken 
versus self-taken rectal and pharyngeal samples for the diagnosis of gonorrhoea and 
chlamydia. Accepted by Clin Infect Dis.] 
 
Instructions were given on swab-taking and insertion into the NAAT specimen containers. 
MSM produced one FCU sample in a 20ml universal container; 2ml were pipetted into a 
NAAT transport medium container for individual analysis and 2ml were pipetted into the 
pooled specimen container. Sampling order was randomised before the study with separate 
randomisation for females and MSM. Laboratory staff were blinded to which were clinician 
and self-taken extragenital samples and the participant origin of the pooled specimens. 
 
Sample pooling 
With Aptima assays (Hologic, San Diego, USA), only one swab shaft can remain in NAAT 
transport medium containers to avoid interference with probe movement. For female pooled 
specimens, the pharyngeal swab was inserted into a VVS transport medium container, 
agitated for 5 seconds, squeezed against the container side during removal to extract as 
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much material as possible and discarded. Cell lysis is almost instantaneous when swabs are 
inserted into NAAT transport medium so 5 seconds agitation was deemed adequate. A 
rectal swab was inserted into the same container, agitated, squeezed, removed and 
discarded. Lastly, a VVS was inserted into the same container and the stem broken off 
leaving the swab inside. Without inhibition from the other samples, no reduction in VVS 
sensitivity was expected, but with additional detection of rectal and pharyngeal infections. 
For MSM pooled specimens, the pharyngeal swab was processed as above in a NAAT 
transport medium container for urine. A rectal swab was inserted into the same container 
and the stem broken off leaving the swab inside. Lastly, 2ml FCU were pipetted into the 
same container so the volume of fluid was between the recommended fill lines. Without 
inhibition/dilution from the other samples, no reduction in rectal sample sensitivity was 
expected, but with additional detection of urethral and pharyngeal infections.   
 
Microbiological analysis 
The samples were tested for NG and CT using Aptima Combo 2 (AC2). To ensure high 
specificity, equivocal or positive tests were tested further using Aptima-GC or Aptima-CT for 
confirmation. Positive CT samples of MSM were also tested for lymphogranuloma venereum 
(LGV) specific DNA using an in-house PCR. Some participants had clinician-taken cultures 
for NG from urogenital and extragenital sites if clinically indicated.  
 
The patient infected status (PIS) for gonorrhoea or chlamydia was defined as at least two 
confirmed positive NG or CT NAAT samples (one could be pooled specimen). The site-
infected status (SIS) was at least two positive site samples, or one positive site sample and 
positive pooled specimen. A positive NG culture from any site conferred a positive NG PIS 
and SIS for the sites positive. The pooled infected status was defined as pooled sample 
positive and at least one other positive sample.  
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Clinician samples were assumed to have sensitivities of 99%. Sensitivity of 80% or less for 
pooled specimens would be rejected as too low. Fifty NG and CT positive samples would 
detect a significant difference between sensitivities of 80% and 99% with 80% power and 
95% probability. The sensitivity and specificity of clinician-taken rectal and pharyngeal 
swabs plus FCU/VVS analysed individually, and the pooled specimen of self-taken rectal 
and pharyngeal swabs with FCU/VVS, were determined using the PIS and SIS and sub-
classified for sex and urogenital symptoms. Any differences between sensitivities in those 
infected, and specificities in those without infection, were determined using McNemar’s 
test.[18]  
 
Health Economics analysis 
Within-study cost-effectiveness analyses following the National Institute of Health and Care 
Excellence recommendations were undertaken from the perspective of the National Health 
Service (NHS).[19] Cost and outcome data were combined to produce a deterministic and 
probabilistic incremental cost-effectiveness ratio (ICER) based on the correct test result from 
clinician, self-taken and pooled samples. The analyses assumed the estimated cost of 
performing the triple tests analysed individually was £60 and a willingness to pay would not 
exceed this threshold.  
 
The grade of clinician, any urogenital symptoms, time taken to perform clinician swabs, and 
the participant’s first set of swabs, were recorded. NHS unit costs were used.[20] Diagnostic 
kit and processing costs were obtained from the Department of Microbiology. Swab 
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A STARD diagram of participant recruitment is shown in Figure 1. In total, 1793 participants 
(1284 females, 509 MSM) were recruited by 5 clinicians. 
 
In females, the mean age was 25 years (range 16-71; median 23 years) and 489 (38.1%) 
had urogenital symptoms in keeping with a bacterial STI. In MSM, the mean age was 33 
years (range 18-77; median 29 years) and 66 (13.0%) had urogenital symptoms in keeping 
with a bacterial STI.  
 
 
Neisseria gonorrhoeae and Chlamydia trachomatis results 
The numbers fulfilling the PIS for NG were 116 (9%); 64 (5%) females and 52 (10.2%) MSM. 
The numbers fulfilling the PIS for CT were 276 (15.4%); 237 (18.5%) females and 39 (7.7%) 
MSM. 
 
Three NG pooled (two PIS positive) and three CT pooled (available samples supporting 
negative PIS) were missing. Four NG pooled (two categorised true positives, two as false 
positives) and five CT pooled samples (four categorised true positives, one as false positive) 
were indeterminate (see supplementary figures s1 and s2). Details of the other missing and 
indeterminate results are described elsewhere, [Wilson JD, Wallace HE, Loftus-Keeling M, 
et al. Swab-yourself trial with economic monitoring and testing for infections collectively 
(SYSTEMATIC): Part 1. A diagnostic accuracy, and cost-effectiveness, study comparing 
clinician-taken versus self-taken rectal and pharyngeal samples for the diagnosis of 
gonorrhoea and chlamydia. Accepted by Clin Infect Dis.] and in Supplementary Figures 3 
and 4. 
 
Figure 2 shows sensitivities, and Table 1 specificities, positive predictive values (PPV) and 
negative predictive values (NPV) of clinician-taken rectal, pharyngeal, with VVS/FCU 
samples, analysed individually; self-taken rectal, pharyngeal, plus VVS/FCU samples, 
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analysed individually; VVS/FCU samples only, and self-taken pooled specimens, for the 
detection of NG and CT as defined by PIS. Clinician-samples, and self-taken samples 
analysed individually identified over 99% of NG and CT infections, and pooled specimens 
over 98% of NG with no significant difference in all participants, females and MSM. 
However, CT pooled specimen sensitivity of 96% was significantly lower than clinician-taken 
samples of 99%, which identified nine more infected people. Pooled specimens missed 13 
infected people. In 9 females these were one NG urogenital; and for CT, 3 urogenital+rectal, 
one rectal+pharyngeal, one pharyngeal and 3 rectal infections. In 4 MSM these were one 
NG rectal; and for CT, one pharyngeal and 2 rectal infections.  
 
Of the 39 MSM with chlamydia, LGV results were unavailable in 4/39. Two of 35 (0.4% of 
total CT positive and LGV tested) MSM had LGV; one positive on rectal and pooled 
specimen; one positive on rectal and equivocal on pooled specimen. 
 
The sensitivities of self-taken swabs analysed individually (98.28%) and self-taken pooled 
swabs (98.25%) for gonorrhoea were almost identical indicating that pooling did not 
introduce inhibition or dilution. However, self-taken swabs analysed individually identified ten 
additional people with chlamydia than pooled specimens, giving a significant reduction in 
sensitivity from 99.6% to 96.0%, The reduction in pooled sensitivity was greater in MSM 
(92.3%) than females (96.6%), suggesting urine did cause dilution leading to false-negative 
results, but due to small numbers of chlamydia in MSM, was not significant (p= 0.19; 
Fisher’s exact test). 
 
However, if analysing only one NAAT sample, pooled specimens were significantly better at 
identifying people with gonorrhoea and chlamydia than VVS/FCU samples. The VVS missed 
seven NG (sensitivity 88.7%) and 31 CT infections (sensitivity 86.9%) and FCU missed 35 
NG (sensitivity 33.3%) and 27 CT infections (sensitivity 29.7%). 
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There were more false positive results in self-taken than clinician-taken samples indicating 
that nucleic acid contamination can occur when people take their own swabs.[21,22] 
However, there were fewer false positive results with pooled specimens, than self-taken 
swabs analysed individually, suggesting our pooling process itself did not increase the risk of 
contamination.  
 
At least one urogenital symptom was reported by 555 (31%) of the participants; 53 (9.5%) 
and 94 (16.9%) were infected with NG and CT respectively. Table 2 shows the sensitivities, 
specificities, PPV and NPV of clinician-samples analysed individually, and pooled 
specimens, for the detection of NG and CT in those with, and without, urogenital symptoms. 
There were no differences between sensitivities of clinician-taken or self-taken samples 
analysed individually versus pooled specimens in NG and CT detection in those with and 
without symptoms. There were also no differences in pooled sensitivities for NG detection 
(OR 1.12, [95%CI 0.07-19.60], p=1.0), or for CT (OR 0.72 [95%CI 0.19-2.77], p=0.75) 
between those with and without symptoms. 
 
Health Economics analysis 
Clinicians performed the swabs in an average of 3 minutes irrespective of grade, whereas 
participants required an average of 4 minutes. Females took longer than MSM (4.2 versus 
3.7 minutes) but clinicians performed the swabs quicker in females (2.9 versus 3.1). 
Symptomatic participants took longer to take their swabs than those asymptomatic (4.3 
versus 3.9) and clinicians took longer to perform swabs on those with symptoms than those 
without (3.7 versus 2.7). Estimated costs of self-taken pooled samples and clinician-taken 
rectal, pharyngeal and FCU/VVS analysed individually are shown in Table 3. Results of the 
cost-effectiveness analysis are shown in Table 4. Pooled specimens were the most cost-
effective method in every scenario, mainly due to savings of £16 on NAAT diagnostic costs. 
The results were robust as the probability of cost-effectiveness was high. Greater than 25% 
reduction of pooled specimen effectiveness would be needed for clinician-samples to have 
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an ICER of £60. Clinician samples for symptomatic participants were the most expensive as 




This trial of clinician-taken samples analysed individually versus pooled self-taken rectal, 
pharyngeal, and urogenital samples in females and MSM demonstrated good concordance 
for the detection of gonorrhoea. The pooled sensitivity for chlamydia at 96% was significantly 
lower than clinician-taken samples analysed individually with sensitivity >99%. Despite this 
reduced chlamydia sensitivity, all sensitivities were over the recommended 90% for 
NAATs.[23] If budgets allow only one NAAT to be analysed, pooled specimens were 
significantly better at identifying people with gonorrhoea and chlamydia than a VVS/FCU. 
 
Six studies have compared pooled triple-site samples with individually analysed 
samples.[12-17] The details are shown in table 5. Pooled sensitivities were all reduced to 
approximately 90%. All confirmed positive NAATs were considered true positives. This is 
likely to overestimate some pooled sensitivities if, as in our study, there were more false 
positive self-taken than clinician-taken swabs (we required at least one other confirmed 
positive sample for the pooled specimen to be categorized true positive). Three studies 
pooled the triple-site specimens in the laboratory.[14,15,17] The others, as in this study, 
pooled the samples immediately after being taken using different techniques; Sultan used 
two techniques within one study.[12]  
 
Our pooled NG and CT sensitivities at 98% and 96% were high compared with these 
studies. Two also used AC2[12,16] but others used different NAATs, and sensitivities vary 
between NAATs[24]. AC2 has high sensitivity for CT and NG which might explain the 
differences. However, Sultan and Durukan[12,16] reported NG sensitivities of 90% and 91% 
compared with our 98% and CT  sensitivities of 92% and 86% compared with our 96%. We 
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believe our pooling method and retention of VVS (female) and rectal swab (MSM) within the 
transport medium increased sensitivity. Also, previous authors suggest reduced pooled 
sensitivity may be from urine volume dilution on single site infections with low bacterial 
loads.[13,14,16] Our results support this suggestion, as pooled sensitivities were higher in 
females (no urine added) than MSM. All our MSM false negative pooled specimens had 
single site infections. These were possibly low bacterial-load infections that dropped below 
the level of detection as urine diluted the pooled samples. We used 2ml FCU in MSM 
pooling whereas some studies used more. To improve sensitivity, future MSM pooling 
studies should use the minimal volume of FCU or another urethral sample, such as meatal 
swabs, to avoid this dilution.[25]  
 
In every scenario, pooled specimens were much more cost-effective than samples analysed 
individually. Pooling could be utilised for self-taken samples in asymptomatic testing, and 
clinician-taken samples when assessing those with urogenital symptoms, as there was no 
difference in sensitivities between pooled specimens in those with and without symptoms. 
 
To optimise specificity, our self-swabbing written instructions included details about reducing 
environmental contamination. [Wilson JD, Wallace HE, Loftus-Keeling M, et al. Swab-
yourself trial with economic monitoring and testing for infections collectively (SYSTEMATIC): 
Part 1. A diagnostic accuracy, and cost-effectiveness, study comparing clinician-taken 
versus self-taken rectal and pharyngeal samples for the diagnosis of gonorrhoea and 
chlamydia. Accepted by Clin Infect Dis.] Even with these there were more false positive self-
taken than clinician swabs, indicating that nucleic acid contamination occurs when people 
take their own swabs. Reassuringly, pooling itself did not increase nucleic acid 
contamination. In fact, the dilution of pooling may reduce low levels of environmental 
contamination to below the limits of detection. In the end, all specificities, of all samples, 
were over 99%. 
 
SYSTEMATIC Part 2 version 2 
14 
 
Limitations of our study are that it was single-centred and assessed only one NAAT. Our 
results cannot necessarily be extrapolated to other NAATs as sensitivities and specificities 
vary between them, and some are affected by inhibitors.[24] The planned allocation of 
female to MSM, to achieve 50 cases of each infection at each site, gave only 39 CT 
infections in MSM which underpowered the MSM CT sub-analyses.  
 
A limitation of a positive pooled specimen is that it does not identify the infected site. This 
only matters if different treatments are recommended for different infected sites, because 
pooled specimens can be used for tests of cure. The same first-line gonorrhoea treatment is 
recommended for all infected sites.[3,5] Azithromycin 1g single dose has been used for 
urogenital chlamydia but its estimated efficacy (82.9%) is lower than doxycycline (99.6%) for 
rectal chlamydia so its use has been questioned.[26,27] Consequently, many guidelines no 
longer recommend single dose azithromycin for chlamydia treatment.[28] Unless single dose 
azithromycin is being used, it is not necessary to know the sites of chlamydia infection for 
most people, as doxycycline is effective at all sites.[28] However, MSM with rectal 
symptoms, and without symptoms if living with HIV, should be LGV tested if CT positive.[29] 
We found only two LGV infections (but MSM with rectal symptoms had been excluded from 
the study); one pooled specimen was positive, the other equivocal. These numbers are 
clearly too small to draw any conclusions on the sensitivity of pooled specimens to detect 
LGV. This should be assessed in future studies. 
 
In summary, if affordable, triple-site samples analysed individually were most sensitive for 
diagnosing gonorrhoea and chlamydia. There was no significant difference in diagnostic 
accuracy between triple-site samples analysed individually, and those pooled, for the 
diagnosis of gonorrhea but pooling samples reduced chlamydia sensitivity by 3% in females 
and 5% in MSM. However, gonorrhoea and chlamydia detection was higher in pooled 
NAATs than VVS/FCU NAATs, for the same diagnostic cost. The small reduction in pooled 
chlamydia sensitivity was more than offset by the large reduction in cost of triple NAATs, 
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meaning that pooled specimens were the most cost-effective way of diagnosing all 
gonorrhoea and chlamydia infections.  
 
These findings have important implications for policy makers and providers of STI services. 
Even in high-income countries, publicly funded health systems struggle to fund triple NAATs 
in MSM, let alone in females, even though evidence of their benefit in identifying additional 
infections is undisputed. However, pooling enables triple-site testing, for the same diagnostic 
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Table 1. Sensitivities, specificities, PPV, and NPV of clinician-taken rectal, pharyngeal, plus VVS/FCU samples, analysed individually; self-taken rectal, pharyngeal 
plus VVS/FCU samples, analysed individually; VVS/FCU samples only, and self-taken pooled samples, for the detection of gonorrhoea and chlamydia in all 
participants, females, and MSM. 
 
Neisseria gonorrhoeae All Participants 116/1793 (6.5%) Neisseria gonorrhoeae All Females 64/1284 (5%) Neisseria gonorrhoeae All MSM 52/509 (10.2%) 
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N = 62/1282 
(2 missing; 














N = 51/506 
(3 missing; 






























N = 62/1281 
(3 missing; 

























112 3 1673 2 61 1 1218 1 51 2 455 1 
Chlamydia trachomatis All Participants 276/1793 (15.4%) Chlamydia trachomatis All Females 237/1284 (18.5%) Chlamydia trachomatis All MSM 39/509 (7.7%) 






























True positive False positive True negative False negative True positive False positive True negative False negative True positive False positive True negative False negative 
















































































































































N = 37/506 
(3 missing; 



























































265 7 1507 11 229 6 1038 8 36 1 469 3 
Missing samples are from negative PIS unless stated from positive PIS 
Sens = Sensitivity; Spec = Specificity 
aP values compared with pooled using  two-tailed McNemar’s test  
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Table 2. Sensitivities, specificities, PPV, NPV, of the clinician-taken samples analysed individually and the self-taken pooled specimens for the detection of 







































































P = 0.48 
 
53 0 502 0 62 2 1173 1 
Pooled 
N = 52/554 
(a1 missing; 








N = 62/1236 
(a2 missing; 









51 0 501 1 61 3 1172 1 



























































P = 0.07 
 
94 0 461 0 180 4 1052 2 
Pooled 
N = 94/554 
(a2 missing; 










N = 182/1237 
(a1 missing; 









91 3 456 3 174 4 1051 8 
aMissing samples are from negative PIS unless stated from positive PIS;  
bP value comparing clinician swabs plus VVS/FPU with pooled using  two-tailed McNemar’s test  
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Self-taken pooled samples Clinician-taken samples analysed individually 
All 
MSM £22.25 
























Women £37.05 £50.21 Women £39.28 £68.43 
Asymptomatic 




Band 3 HCA 
not applicable 
     
Women £9.76 £22.92      
 
aAssumes self-taken samples overseen by Band 3 Health Care Assistants (Nursing Assistants) 
b£1.72 per test kit, three test kits are still needed for the swabs for the pooled processed tests  
c£8.00 to processing each NAAT  
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Table 4. The cost-effectiveness analysis of the clinician-taken swabs individually analysed versus the self-taken pooled swabs for the diagnosis of gonorrhoea 
and chlamydia in those with and without urogenital symptoms. 
 
aICER = incremental cost-effectiveness ratio; 
bProbability of CE at a WTP of £60 = Probability of cost-effectiveness at a willingness to pay of £60 
Negative ICER represents the alternative is dominated as it is costlier and less effective 
Rows in bold represent the cost-effective strategy at a £60 per correct test detected assumed. Cost-effective strategies have a higher net monetary benefit 







benefit                                                 
(£60 threshold) 
bProbability of 




Pooled £4,483 94.00      £1,157 1.0 
Individually £6,002 94.43 £1,519 0.43 £3,515 -£336 0.0 
Women 
Pooled £27,545 545.97      £5,213 1.0 
Individually £36,304 536.99 £8,759 -8.98 -£974 -£4,085 0.0 
Asymptomatic 
MSM 
Pooled £13,178 411.96      £11,539 1.0 
Individually £19,802 408.95 £6,623 -3.00 -£2,201 £4,735 0.0 
Women 
Pooled £22,321 734.83      £21,769 1.0 
Individually £34,091 733.95 £11,770 -0.88 -£13,352 £9,945 0.0 







benefit                                                                                                                      
(£60 threshold) 
bProbability of 




Pooled £18,024.96 504.98       £12,274 1.0 
Individually £25,754.59 507.98 £7,729.63 3.00 £2,574.53 £4,724 0.0 
Women 
Pooled £50,118.00 1266.87       £25,894 1.0 
Individually £70,655.31 1262.95 £20,537.32 -3.93 -£5,227.21 £5,121 0.0 
Asymptomatic 
MSM 
Pooled £13,178.91 411.09       £11,486 1.0 
Individually £19,802.37 413.17 £6,623.46 2.08 £3,182.48 £4,988 0.0 
Women 
Pooled £22,321.42 724.94       £21,175 1.0 
Individually £34,091.83 722.95 £11,770.40 -1.99 -£5,912.90 £9,285 0.0 




Table 5. Details of published studies comparing triple-site swabs taken for pooled samples with swabs for individually analysed samples, plus results in MSM 




Sultan12 Thielemans13 Speers14 De Baetselier15 Durukan16 De Baetselier17 Wilson Wilson 
Participants  MSM only MSM only MSM only MSM only MSM only MSM only MSM Women 
Total participants 1064 100 107 
98 giving 117 sample 
sets 
162 all with recent 
positive individual 
site sample 
497 509 1284 
Swab order Randomised Individual first 
Together, 
dual-headed swabs  
Samples for pooling 





Samples for pooling 


























































Timing of pooling 
As soon as swabs 
taken 










As soon as swabs 
taken 
As soon as swabs 
taken 
Swab left in pooled 
specimen 
None Both 
Both but pooled in 
laboratory 
Both but pooled in 
laboratory 
Pharyngeal 
Both but pooled in 
laboratory 
Rectal in MSM VVS in women 




Method B 2ml 
3ml 7ml 1.7ml 2ml 4µL 2ml None 
NAAT used for 
pooled samples 
Hologic AC2 
Abbott Real Time 
CT/GC test 
Cepheid GeneXpert 
Abbott Real Time 
CT/GC test 
Hologic AC2 Cepheid GeneXpert Hologic AC2 Hologic AC2 
NAAT used for 
individual samples 
Hologic AC2 
Abbott Real Time 
CT/GC test 
Roche cobas 4800 
Abbott Real Time 
CT/GC test 
Hologic AC2 
Abbott Real Time 
CT/GC test 
Hologic AC2 Hologic AC2 
Number (prevalence) 
with NG 
292  (27%) 12  (12%) 34  (32%) 8   (7%) 80  (49%) 57  (11.5%) 52  (10%) 64  (5%) 
Number (prevalence) 
with CT 
168  (16%) 10  (10%) 20  (19%) 11  (9%) 109  (67%) 72  (14.5%) 39  (8%) 276  (19%) 
Sensitivity (95% CI) 
pooled NG 
89.9% (85.8-93.1) 89.5% (68.6-97.1)a 100% (89.7-100.0) 100% (63.1-100.0) 91.3% (83.0-95.1) 88.9% (77.4-95.8) 98.1% (89.7-100) 98.4% (91.3-100) 
Sensitivity (95% CI) 
pooled CT 
91.9% (86.5- 95.6) 89.5% (68.6-97.1)a 77.8% (52.4-93.6) 81.8% (48.2-97.7) 86.2% (78.5-91.5) 95.4% (87.1-99.0) 92.3% (79.1-98.4) 96.6% (93.5-98.5) 
aNG and CT combined analysis due to small numbers but pooled in laboratory 





Figure 1. STARD Diagram SYSTEMATIC 









Figure 2. Sensitivities of clinician-taken rectal, pharyngeal, plus VVS/FCU samples, analysed individually; self-taken triple-site pooled samples; 
and single site VVS/FCU only; for the detection of gonorrhoea and chlamydia in all participants, females, and MSM. 
 
